skip to main content

Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms, hedge funds, financial advisors and other financial institutions and investors on their most important merger, acquisitions and takeover transactions.

Alexion Pharmaceuticals Completes Acquisition of Portola Pharmaceuticals

Paul, Weiss advised Alexion Pharmaceuticals, Inc. in its acquisition of Portola Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Under the terms of the transaction, Alexion acquired all of Portola’s outstanding shares of common stock at $18.00 per share in cash, without interest.

The Paul, Weiss team included corporate partners Rachael Coffey, Scott Barshay, Caith Kushner, John Kennedy and Raphael Russo and counsel Patricia Vaz de Almeida; intellectual property partner Jonathan Ashtor; employee benefits partner Jean McLoughlin and counsel Reuven Falik and Jarrett Hoffman; litigation partners Rick Rule, Jaren Janghorbani and Eric Stone and counsel Rachel Fiorill; tax partner Robert Holo; real estate partner Peter Fisch; and antitrust counsel Yuni Sobel and Marta Kelly

July 2, 2020

© 2020 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy